ENTYVIO Market Drug Insight and Market Forecast - 2032

“ENTYVIO Market Drug Insight and Market Forecast - 2032” report provides comprehensive insights about ENTYVIO for Ulcerative Colitis (UC) in the seven major markets. A detailed picture of the ENTYVIO for ulcerative colitis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ENTYVIO for ulcerative colitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ENTYVIO market forecast analysis for ulcerative colitis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ulcerative colitis.

Drug Summary

ENTYVIO (Vedolizumab) is a gut-selective biologic developed by Takeda Pharmaceutical and marketed under the trade name ENTYVIO. It is approved in the US for the treatment of adult patients with moderately to severely active UC and Crohn's disease (CD), who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα)-antagonist. It is a humanized monoclonal antibody designed to specifically antagonize the alpha 4 beta 7 integrin, inhibiting the binding of alpha 4 beta 7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not Vascular Cell Adhesion Molecule 1 (VCAM-1). MAdCAM-1 is preferentially expressed on the gastrointestinal tract's blood vessels, and lymph nodes. The alpha 4 beta 7 integrin is expressed on a subset of circulating white blood cells, and these cells have been shown to play a role in mediating the inflammatory process in UC and CD. By inhibiting alpha 4 beta 7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.

Dosage
The recommended dosage of ENTYVIO in adults with UC is 300 mg administered by intravenous infusion at 0, 2, and 6 weeks and then every 8 weeks thereafter. Therapy should be discontinued in patients who show no evidence of therapeutic benefit by Week 14.

Mechanism of Action

Vedolizumab is a humanized monoclonal antibody that specifically binds to the α4β7 integrin and blocks the interaction of α4β7 integrin with mucosal addressin cell adhesion molecule-1 (MAdCAM-1), and inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue. Vedolizumab does not bind to or inhibit the function of the α4β1 and αEβ7 integrins and does not antagonize the interaction of α4 integrins with vascular cell adhesion molecule-1 (VCAM-1).

The α4β7 integrin is expressed on the surface of a discrete subset of memory T-lymphocytes that preferentially migrate into the gastrointestinal tract. MAdCAM-1 is mainly expressed on gut endothelial cells and plays a critical role in homing T-lymphocytes to gut lymph tissue. The interaction of the α4β7 integrin with MAdCAM-1 has been an important contributor to the chronic inflammation that is a hallmark of UC and CD.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the ENTYVIO description, mechanism of action, dosage and administration, research and development activities in ulcerative colitis.
• Elaborated details on ENTYVIO regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ENTYVIO research and development activities in ulcerative colitis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ENTYVIO.
• The report contains forecasted sales of for ulcerative colitis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ulcerative colitis.
• The report also features the SWOT analysis with analyst views for ENTYVIO in ulcerative colitis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ENTYVIO Analytical Perspective

In-depth ENTYVIO Market Assessment

This report provides a detailed market assessment of ENTYVIO for ulcerative colitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

ENTYVIO Clinical Assessment

The report provides the clinical trials information of ENTYVIO for ulcerative colitis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for ulcerative colitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ENTYVIO dominance.
• Other emerging products for ulcerative colitis are expected to give tough market competition to ENTYVIO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ENTYVIO in ulcerative colitis.
• This in-depth analysis of the forecasted sales data of ENTYVIO from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ENTYVIO in ulcerative colitis.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of ENTYVIO?
• What is the clinical trial status of the study related to ENTYVIO in ulcerative colitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ENTYVIO development?
• What are the key designations that have been granted to ENTYVIO for ulcerative colitis?
• What is the forecasted market scenario of ENTYVIO for ulcerative colitis?
• What are the forecasted sales of ENTYVIO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ENTYVIO for ulcerative colitis?
• Which are the late-stage emerging therapies under development for the treatment of ulcerative colitis?

This product will be delivered within 2 business days.